Viralgen and Axovia to develop gene therapy for retinal dystrophy

Viralgen and Axovia collaborate to manufacture gene therapy for rare disease vision loss

The gene therapy aims to stop retinal dystrophy in people with Bardet-Biedl Syndrome.

Viralgen and Axovia to develop gene therapy for retinal dystrophy

Viralgen and Axovia are set to form a partnership to progress the development and manufacturing of gene therapy for retinal dystrophy

Axovia teams with contract development and manufacturing organization Viralgen to produce BBS gene therapy

Axovia teams with contract development and manufacturing organization Viralgen to produce BBS gene therapy using AAV cell line platform technology

Seeing the Light with Retinal Gene Therapy - BioPatrika

Seeing the Light with Retinal Gene Therapy: From Fantasy to Reality with Jean Bennett, M.D., Ph.D., University of Pennsylvania Perelman School of Medicine. In this episode of the Cell & Gene Therapy Series: Pies of Life (Mentorship), Dr. Jean Bennett, a world leader and pioneering physician-scientist in the field of retinal (eye) gene therapy, discusses […] The post Seeing the Light with Retinal Gene Therapy appeared first on BioPatrika.